POLIDOCANOL A 1% COMO OPÇÃO AO TRATAMENTO CIRÚRGICO DOS HEMANGIOMAS ORAIS: RELATO DE CASOS CLÍNICOS

• Autor(a) principal: Ferreira Santana, José Vanison
• Data de Publicação: 2024
• Outros Autores: Teles Freire, Rangel, de Souza Amorim, Klinger, de Santana Oliveira, Iris Tamara, Souza Rios, Monique Lorem, Maciel de Almeida , Liane
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Brazilian Journal of Implantology and Health Sciences
• Texto Completo: https://bjihs.emnuvens.com.br/bjihs/article/view/1329
• topic: Polidocanol; Esclerosante; Hemangioma

Hemangioma is a common benign neoplasm in the head and neck region, and its persistence after the age of nine is relatively rare. Sclerosing treatment is an effective, conservative, minimally invasive technique, which results in the elimination of aesthetic and functional changes in the injured area, without involving the risks of hemorrhage found in surgical treatment, in addition to providing resolution in a short time. One of the sclerosing agents used for many years in the treatment of hemangioma and varicose veins is polidocanol. The use of this sclerosant has advantages such as an additional anesthetic effect in the absence of pain during intravascular injection, a high level of efficacy and safety and a very low occurrence rate of allergic reactions. Considering the usefulness of this substance, its numerous practical applications in the medical field and its little widespread use in the dental world, this study aims to evaluate the biological response of 1% polidocanol in hemangiomas, located in the oral mucosa.